Cryoballoon ablation for treatment of patients with refractory esophageal neoplasia after first line endoscopic eradication therapy

Abstract

Background and study aims Cryoablation with the Cryoballoon device is a novel ablative therapy that uses cycles of freezing and thawing to induce cell death. This single-center prospective study evaluated the feasibility of the focal cryoablation device for the treatment of areas of refractory esophageal neoplasia in patients who had undergone first line endoscopic eradication therapy (EET). Complete remission of dysplasia (CR-D) and complete remission of intestinal metaplasia (CR-IM) at first follow-up endoscopy, durability of disease reversal, rates of stenosis and adverse events were studied.

Patients and methods Eighteen cases were treated. At baseline, nine patients had low-grade dysplasia (LGD), six had high-grade dysplasia (HGD) and three had intramucosal carcinoma (IMC). Median length of dysplastic Barrett’s esophagus (BE) treated was 3 cm. The median number of ablations per patient was 11. Each selected area of visible dysplasia received 10 seconds of ablation. One session of cryoablation was performed per patient. Biopsies were performed at around 3 months post-ablation.

Results CR-D was achieved in 78 % and CR-IM in 39 % of patients. There were no device malfunction or adverse events. Stenosis was noted in 11 % of cases. At a median follow up of 19-months, CR-D was maintained in 72 % of patients and CR-IM in 33 %.

Conclusions Cryoablation appears to be a viable rescue strategy in patients with refractory neoplasia. It is well tolerated and successful in obtaining CR-D and CR-IM in patients with treatment-refractory BE. Further trials of dosimetry, efficacy and safety in treatment-naïve patients are underway.

Publication History

Received: 04 December 2019

Accepted: 12 February 2020

Article published online:
16 June 2020

• References

• 1 Spechler SJ. Barrett’s esophagus and esophageal adenocarcinoma: pathogenesis, diagnosis, and therapy. Med Clin North Am 2002; 86: 1423-1445
• 2 Poehlmann A, Kuester D, Malfertheiner P. et al. Inflammation and Barrett’s carcinogenesis. Pathol Res Pract 2012; 208: 269-280
• 3 Pohl H, Welch H. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst 2005; 97: 142-146
• 4 Hur C, Miller M, Kong CY. et al. Trends in esophageal adenocarcinoma incidence and mortality. Cancer 2013; 119: 1149-1158
• 5 Hvid-Jensen F, Pedersen L, Drewes AM. et al. Incidence of adenocarcinoma among patients with Barrett’s esophagus. N Engl J Med 2009; 365: 2301-2303
• 6 Fernando HC, Murthy SC, Hofstetter W. et al. The Society of Thoracic Surgeons Practice Guideline Series: Guidelines for the Management of Barrett’s Esophagus With High-Grade Dysplasia. AnnThorac Surg 2009; 87: 1993-2002
• 7 Prasad G, Wang K, Buttar N. et al. Long-term survival following endoscopic and surgical treatment of high-grade dysplasia in Barrett’s esophagus. Gastroenterology 2007; 132: 1226-1233
• 8 Stein HJ, Hutter J, Feith M. et al. Limited surgical resection and jejunal interposition for early adenocarcinoma of the distal esophagus. Semin Thorac Cardiovasc Surg 2007; 19: 72-78
• 9 Shimada H, Nabeya Y, Matsubara H. et al. Prediction of lymph node status in patients with superficial esophageal carcinoma: Analysis of 160 surgically resected cancers. Am J Surg 2006; 191: 250-254
• 10 Lipman G, Haidry R. Endoscopic management of Barrett’s and early oesophageal neoplasia. Frontline Gastroenterol 2017; 8: 138-142
• 11 Ganz RA, Utley DS, Stern RA. et al. Complete ablation of esophageal epithelium with a balloon-based bipolar electrode: A phased evaluation in the porcine and in the human esophagus. Gastrointest Endosc 2004; 60: 1002-1010
• 12 Phoa K, Pouw R, Bisschops R. et al. Multimodality endoscopic eradication for neoplastic Barrett oesophagus: Results of an European multicentre study (EURO-II). Gut 2016; 65: 555-662
• 13 Desai M, Saligram S, Gupta N. et al. Efficacy and safety outcomes of multimodal endoscopic eradication therapy in Barrett’s esophagus-related neoplasia: a systematic review and pooled analysis. Gastrointest Endosc 2017; 85: 482-495
• 14 Haidry RJ, Lipman G, Banks M. et al. Comparing outcome of radiofrequency ablation in Barrett’s with high grade dysplasia and intramucosal carcinoma: A prospective multicenter UK registry. Endoscopy 2015; 47: 980-987
• 15 Pasricha S, Bulsiewicz W, Hathorn K. et al. Durability and predictors of successful radiofrequency ablation for Barrett’s esophagus. Clin Gastroenterol Hepatol 2014; 12: 1840-1847
• 16 Krishnamoorthi R, Singh S, Ragunathan K. et al. Risk of recurrence of Barrett’s esophagus after successful endoscopic therapy. Gastrointest Endosc 2016; 83: 1090-1106
• 17 Sengupta N, Ketwaroo GA, Bak DM. et al. Salvage cryotherapy after failed radiofrequency ablation for Barrettʼs esophagus – related dysplasia is safe and effective. Gastrointest Endosc 2015; 82: 443-448
• 18 Gage A, Baust J. Mechanisms of tissue injury in cryosurgery. Cryobiology 1998; 37: 171-186
• 19 Baust J, Gage A, Klossner D. et al. Issues critical to the successful application of cryosurgical ablation of the prostate. Technol Cancer Res Treat 2007; 6: 97-109
• 20 Evonich R, Nori D, Haines D. A randomized trial comparing effects of radiofrequency and cryoablation on the structural integrity of esophageal tissue. J Interv Card Electrophysiol 2007; 19: 77-83
• 21 Künzli H, Schölvinck D, Meijer S. et al. Efficacy of the Cryoballoon focal ablation system for the eradication of dysplastic Barrett’s esophagus islands. Endoscopy 2016; 49: 169-175
• 22 Schölvinck DW, Künzli HT, Kestens C. et al. Treatment of Barrett’ s esophagus with a novel focal cryoablation device: a safety and feasibility study. Endoscopy 2015; 1106-1112
• 23 Van Munster S, Overwater A, Haidry R. et al. Focal cryoballoon versus radiofrequency ablation of dysplastic Barrett’s esophagus: impact on treatment response and postprocedural pain. Gastrointest Endosc 2018; 88: 1-9
• 24 Friedland S, Triadafilopoulos G. A novel device for ablation of abnormal esophageal mucosa (with video). Gastrointest Endosc 2011; 74: 182-188
• 25 Magee C, Gordon C, Dunn J. et al. Outcomes of 360 HALO express radio-frequency ablation for Barrettʼs Oesophagus related neoplasia. Abstract presented at BSG annual conference 2018
• 26 Haidry RJ, Butt MA, Dunn JM. et al. Improvement over time in outcomes for patients undergoing endoscopic therapy for Barrett’s oesophagus-related neoplasia: 6-year experience from the first 500 patients treated in the UK patient registry. Gut 2015; 64: 1192-1199
• 27 Inadomi J, Somsouk M, Madanick D. et al. A cost-utility analysis of ablative therapy for Barrett’s esophagus. Gastroenterology 2009; 136: 2101-2114
• 28 Haidry R, Lovat L. Long-term durability of radiofrequency ablation for Barrett’s-related neoplasia. Curr Opin Gastroenterol 2015; 31: 316-320
• 29 Magee C, Gordon C, Dunn J. et al. Halo 360 express radio-frequency ablation in the treatment of barrett's oesophagus – The first 100 vases treated in the United Kingdom. BSG annual conference; 2017
• 30 Orman E, Nan L, Shaheen N. Efficacy and durability of radiofrequency ablation for barrett’s esophagus: systematic review and meta-analysis. Clin Gastroenterol Hepatol 2013; 11: 1-20
• 31 Gupta M, Iyer P, Lutzke L. et al. Recurrence of Esophageal intestinal metaplasia after endoscopic mucosal resection and radiofrequency ablation of Barrett’s esophagus: Results from a US multicenter consortium recurrence of Barrett’s esophagus after EMR and RFA. Gastroenterology 2013; 145: 79-86
• 32 Pech O, Behrens A, May A. et al. Long-term results and risk factor analysis for recurrence after curative endoscopic therapy in 349 patients with high-grade intraepithelial neoplasia and mucosal adenocarcinoma in Barrett’s oesophagus. Gut 2008; 57: 1200-1206
• 33 Cotton C, Wolf W, Pasricha S. et al. Recurrent intestinal metaplasia after radiofrequency ablation for Barrett’s esophagus: endoscopic findings and anatomic location. Gastrointest Endosc 2015; 81: 1362-1369
• 34 Fasanella K, McGrath K. The Ice Age reborn?. Gastrointest Endosc 2019; 90: 213-214
• 35 Kerry B, Dunbar S. The risk of lymph node metastases in patients with high grade dysplasia or intramucosal carcinoma in Barrett’s Esophagus: a systematic review. Am J Gastroenterol 2012; 107: 850-862
• 36 Yong E, Han X, Watson D. et al. Outcome following surgery for squamous cell carcinoma of the oesophagus. ANZ J Surg 2009; 79: 724-728
• 37 Krishnan K, Pandolfino J, Kahrilas P. et al. Increased risk for persistent intestinal metaplasia in patients with Barrett’s esophagus and uncontrolled reflux exposure before radiofrequency ablation. Gastroenterology 2012; 143: 576-581
• 38 Komanduri S, Kahrilas P, Krishnan K. et al. Recurrence of Barrett’ s esophagus is rare following endoscopic eradication therapy coupled with effective reflux control. Am J Gastroenterol 2017; 112: 556-566
• 39 Gosain S, Mercer K, Twaddell W. et al. Liquid nitrogen spray cryotherapy in Barrett’s esophagus with high-grade dysplasia: Long-term results. Gastrointest Endosc 2013; 78: 260-265
• 40 Dumot J, Vargo J, Falk G. et al. An open-label, prospective trial of cryospray ablation for Barrett’s esophagus high-grade dysplasia and early esophageal cancer in high-risk patients. Gastrointest Endosc 2009; 70: 635-644
• 41 Visrodia K, Zakko L, Singh S. et al. Cryotherapy for persistent Barrett’s esophagus after radiofrequency ablation: a systematic review and meta-analysis. Gastrointest Endosc 2018; 87: 1396-1404
• 42 Yang D, Zou F, Xiong S. et al. Endoscopic submucosal dissection for early Barrett’s neoplasia: a meta-analysis. Gastrointest Endosc 2018; 87: 1383-1393
• 43 Canto M, Shaheen N, Almario J. et al. Multifocal nitrous oxide cryoballoon ablation with or without EMR for treatment of neoplastic Barrett’s esophagus. Gastrointest Endosc 2018; 88: 438-446
• 44 Greenwald B, Dumot J, Abrams J. et al. Endoscopic spray cryotherapy for esophageal cancer: safety and efficacy. Gastrointest Endosc 2010; 71: 686-693
• 45 Van Munster S, Overwater A, Raicu M. et al. A novel cryoballoon ablation system for eradication of dysplastic Barrett’s esophagus: a first-in-human feasibility study. Endoscopy 2020; 52: 193-201
• 46 Canto M. Cryotherapy for Barrett’s esophagus. Gastrointest Endosc Clin N Am 2017; 27: 503-513
• 47 Truesdale C, Soulen M, Clark T. et al. Percutaneous computed tomography-guided renal mass radiofrequency ablation versus cryoablation: Doses of sedation medication used. J Vasc Interv Radiol 2013; 24: 347-350
• 48 Bastani H, Drca N, Insulander P. et al. Cryothermal vs. radiofrequency ablation as atrial flutter therapy: A randomized comparison. Europace 2013; 15: 420-423
• 49 Erinjeri J, Clark T. Cryoablation: Mechanism of action and devices. J Vasc Interv Radiol 2010; 21: S187-S191
• 50 Allaf M, Varkarakis I, Bhayani S. et al. Pain control requirements for percutaneous ablation of renal tumors: cryoablation versus radiofrequency ablation – initial observations. Radiology 2005; 237: 366-370